Exagen Inc at KeyBanc Capital Markets Life Sciences & MedTech Forum (Virtual) Transcript
Hi, it's Paul Knight, the analyst in life science and diagnostics at KeyBanc. Thanks for being here. (Conference Instructions)
We have Ron Rocca, CEO of Exagen; and Kamal Adawi, Chief Financial Officer. I thought, Ron, if you could provide -- I don't know if you have a slideshow, but or -- just a little bit of an intro for those not familiar with Exagen.
Sure. And we have slides.
Okay.
We have slides, but I think it's better if I just talk about it. So we are an autoimmune-focused company, and what that means is strictly with the rheumatologist. Our strategy, our mission if you will, is to own the hilltop. We have a very experienced executive team. And we find that that's the best way to go to market, is to have multiple assets for one specialty category and be able to deliver
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |